Cargando…
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer
Poly (ADP-ribose) polymerase 1 (PARP1) is highly expressed in small cell lung cancer (SCLC) and has emerged as an attractive target for treatment of SCLC. However, the clinical significance of PARP1 expression in SCLC remains elusive. In this study, we showed that high PARP1 expression was associate...
Autores principales: | Bian, Xing, Wang, Xiaolin, Zhang, Qiuyan, Ma, Liying, Cao, Guozhen, Xu, Ao, Han, Jinhua, Huang, Jun, Lin, Wenchu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578565/ https://www.ncbi.nlm.nih.gov/pubmed/33134168 http://dx.doi.org/10.3389/fonc.2020.565820 |
Ejemplares similares
-
Corrigendum: The MYC paralog-PARP1 axis as a potential therapeutic target in MYC paralog-activated small cell lung cancer
por: Bian, Xing, et al.
Publicado: (2023) -
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
por: Dammert, Marcel A., et al.
Publicado: (2019) -
Paralog-based synthetic lethality: rationales and applications
por: Xin, Yucui, et al.
Publicado: (2023) -
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2020) -
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer
por: Ma, Liying, et al.
Publicado: (2021)